Skip to main content
NCBI home page
The Journal of Physiology logoLink to The Journal of Physiology
. 1985 May;362:359–368. doi: 10.1113/jphysiol.1985.sp015683

A dopaminergic receptor modulates catecholamine release from the cat adrenal gland.

A R Artalejo, A G García, C Montiel, P Sánchez-García
PMCID: PMC1192902  PMID: 4020691

Abstract

Nicotine evokes the release of catecholamines from perfused cat adrenal glands in a concentration-dependent manner, the median effective concentration for nicotine being 5 microM. Two 2 min pulses of 5 microM-nicotine, 40 min apart (S1 and S2) gave net catecholamine outputs of 7.64 and 3.55 micrograms/8 min, respectively. The ratio S2/S1 in control glands was 0.5. Increasing concentrations of apomorphine (1-10 microM) markedly inhibited catecholamine release during the second nicotine pulse (S2). At 1 microM-apomorphine, the release during S2 was significantly reduced to 16% of S1; with 10 microM-apomorphine, the secretory response was reduced further to only 3% of S1, the ratio S2/S1 being 0.03. The presence of haloperidol, sulpiride or picobenzide (each 0.5 microM) during S2, completely reversed the inhibition of catecholamine release produced by apomorphine. Haloperidol itself increased the nicotinic secretory response during S2; so, while the ratio S2/S1 was 0.5 in control conditions, this ratio increased significantly to 0.95 if haloperidol (0.5 microM) was present during S2, suggesting that the presence of this dopaminergic antagonist removed a negative feed-back mechanism that inhibits nicotine-evoked catecholamine release. If present during S2, dopamine (1 microM) also markedly inhibited catecholamine release evoked by nicotine; this inhibition was again reversed by 0.5 microM-haloperidol. Neither the opiate antagonist naloxone nor the alpha-adrenoceptor blocking agent phentolamine (at concentrations of 0.5-5 microM) affected the inhibition by apomorphine of the secretory response to nicotine. These data strongly suggest that the cat adrenal medulla chromaffin cell membrane contains a dopaminergic receptor which modulates the catecholamine secretory process triggered by stimulation of the nicotinic cholinoceptor. The fact that dopamine is released in measurable amounts, together with adrenaline and noradrenaline, from perfused cat adrenal glands in response to nicotinic stimulation (V. Ceña, unpublished results), favours a role for this dopaminergic receptor in modulating catecholamine release from the chromaffin cell.

Full text

PDF
359

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bühler H. U., da Prada M., Haefely W., Picotti G. B. Plasma adrenaline, noradrenaline and dopamine in man and different animal species. J Physiol. 1978 Mar;276:311–320. doi: 10.1113/jphysiol.1978.sp012235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CARLSSON A., LINDQVIST M., MAGNUSSON T., WALDECK B. On the presence of 3-hydroxytyramine in brain. Science. 1958 Feb 28;127(3296):471–471. doi: 10.1126/science.127.3296.471. [DOI] [PubMed] [Google Scholar]
  3. Dinerstein R. J., Vannice J., Henderson R. C., Roth L. J., Goldberg L. I., Hoffmann P. C. Histofluorescence techniques provide evidence for dopamine-containing neuronal elements in canine kidney. Science. 1979 Aug 3;205(4405):497–499. doi: 10.1126/science.451614. [DOI] [PubMed] [Google Scholar]
  4. Dubocovich M. L., Langer S. Z. Dopamine and alpha adrenoceptor agonists inhibit neurotransmission in the cat spleen through different presynaptic receptors. J Pharmacol Exp Ther. 1980 Jan;212(1):144–152. [PubMed] [Google Scholar]
  5. Farnebo L. O., Hamberger B. Drug-induced changes in the release of ( 3 H)-noradrenaline from field stimulated rat iris. Br J Pharmacol. 1971 Sep;43(1):97–106. doi: 10.1111/j.1476-5381.1971.tb07160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldberg L. I., Volkman P. H., Kohli J. D. A comparison of the vascular dopamine receptor with other dopamine receptors. Annu Rev Pharmacol Toxicol. 1978;18:57–79. doi: 10.1146/annurev.pa.18.040178.000421. [DOI] [PubMed] [Google Scholar]
  7. Kalsner S., Chan C. C. Inhibition by dopamine of the stimulation-induced efflux of [3H]noradrenaline in renal arteries: limitations of the unitary hypothesis of presynaptic regulation of transmitter release. Can J Physiol Pharmacol. 1980 May;58(5):504–512. doi: 10.1139/y80-084. [DOI] [PubMed] [Google Scholar]
  8. Kebabian J. W., Greengard P. Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science. 1971 Dec 24;174(4016):1346–1349. doi: 10.1126/science.174.4016.1346. [DOI] [PubMed] [Google Scholar]
  9. Kirpekar S. M., Puig M. Effect of flow-stop on noradrenaline release from normal spleens and spleens treated with cocaine, phentolamine or phenoxybenzamine. Br J Pharmacol. 1971 Oct;43(2):359–369. [PMC free article] [PubMed] [Google Scholar]
  10. Ladona M. G., Sanchez-García P., García A. G. Effects of hypertonic solutions on catecholamine release from cat adrenal glands. Neuroscience. 1984 May;12(1):301–307. doi: 10.1016/0306-4522(84)90155-6. [DOI] [PubMed] [Google Scholar]
  11. Langer S. Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1980 Dec;32(4):337–362. [PubMed] [Google Scholar]
  12. Libet B. Generation of slow inhibitory and excitatory postsynaptic potentials. Fed Proc. 1970 Nov-Dec;29(6):1945–1956. [PubMed] [Google Scholar]
  13. Long J. P., Heintz S., Cannon J. G., Kim J. Inhibition of the sympathetic nervous system by 5,6-dihydroxy-2-dimethylamino tetralin (M-7), apomorphine and dopamine. J Pharmacol Exp Ther. 1975 Feb;192(2):336–342. [PubMed] [Google Scholar]
  14. Schiavone M. T., Kirpekar S. M. Inactivation of secretory responses to potassium and nicotine in the cat adrenal medulla. J Pharmacol Exp Ther. 1982 Dec;223(3):743–749. [PubMed] [Google Scholar]
  15. Shellenberger M. K., Gordon J. H. A rapid, simplified procedure for simultaneous assay of norepinephrine, dopamine, and 5-hydroxytryptamine from discrete brain areas. Anal Biochem. 1971 Feb;39(2):356–372. doi: 10.1016/0003-2697(71)90426-x. [DOI] [PubMed] [Google Scholar]
  16. Starke K. Influence of -receptor stimulants on noradrenaline release. Naturwissenschaften. 1971 Aug;58(8):420–420. doi: 10.1007/BF00591535. [DOI] [PubMed] [Google Scholar]
  17. Steinsland O. S., Hieble J. P. Dopaminergic inhibition of adrenergic neurotransmission as a model for studies on dopamine receptor mechanisms. Science. 1978 Jan 27;199(4327):443–445. doi: 10.1126/science.22933. [DOI] [PubMed] [Google Scholar]
  18. Stjärne L., Brundin J. Beta2-adrenoceptors facilitating noradrenaline secretion from human vasoconstrictor nerves. Acta Physiol Scand. 1976 Mar;97(1):88–93. doi: 10.1111/j.1748-1716.1976.tb10238.x. [DOI] [PubMed] [Google Scholar]
  19. Westfall T. C. Local regulation of adrenergic neurotransmission. Physiol Rev. 1977 Oct;57(4):659–728. doi: 10.1152/physrev.1977.57.4.659. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Physiology are provided here courtesy of The Physiological Society

RESOURCES